Cellid proposes Korean IPO

Cell-based vaccine company Cellid Co. Ltd. (Seoul, South Korea) proposed on Dec. 13 to sell 1.2 million shares at W22,100-W27,000 in a Korean IPO, according to the Korean Stock Exchange's website. At the W24,550 mid-point, Cellid would raise W29.5 billion ($26.2 million) and be valued at W230.8 billion ($205.2 million).

The company's lead product is BVAC-C, a B cell vaccine based on E6 transforming protein (human papillomavirus-16; HpV16gp1), E7 transforming protein (human papillomavirus-18; HpV18gp2), HpV16gp2 and HpV18gp1. It is in a Phase I/II trial for HPV type 16 or 18-positive cervical cancer...